Tirzepatide: difference between revisions
Diff·revision 17 → 18·05:43, 28 Feb 2025
Difference between revision 17 and revision 18 of Tirzepatide. 3 lines changed; the page grew by 95 bytes.
| Revision 17 — 07:22, 8 Feb 2025 IcodecIndra (talk) expand §Adverse effects and tolerability 6,234 bytes +845 | Revision 18 — 05:43, 28 Feb 2025 OralSemaOswin (talk) give the INN alongside the trade name at first mention 6,329 bytes +95 | ||
|---|---|---|---|
| 17 | | Bioavailability, SC = ≈80% | 17 | | Bioavailability, SC = ≈80% |
| 18 | | Time to steady state = 4 weeks | 18 | | Time to steady state = 4 weeks |
| + | 19 | <!-- Doses --> | |
| + | 20 | | Starting = 2.5 mg weekly for 4 weeks | |
| + | 21 | | Maintenance = 5, 10 or 15 mg weekly | |
| 19 | }} | 22 | }} |
| 20 | {{hatnote|Not to be confused with [[Retatrutide]], which adds glucagon-receptor agonism. For the class, see [[Dual incretin agonist]].}} | 23 | {{hatnote|Not to be confused with [[Retatrutide]], which adds glucagon-receptor agonism. For the class, see [[Dual incretin agonist]].}} |